Latest Breaking News On - கொரியா முதலீடு கூட்டாளர்கள் - Page 5 : comparemela.com

Swiggy Closes $1 25 Bn Series J Funding Round At $5 5 Bn Valuation

Swiggy Closes $1 25 Bn Series J Funding Round At $5 5 Bn Valuation
inc42.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inc42.com Daily Mail and Mail on Sunday newspapers.

New zealand generalNew zealandSouth koreaMeituan dianpingSriharsha majetySoftbank vision fundQatar investment authorityGoldman sachsFalcon edge capitalAmansa capitalThink investmentsAccel partnersData scienceSpark impactKorea investment partnersSwiggy genie

바로고, 생각대로 인수 검토…대규모 배달대행업체 탄생하나

바로고, 생각대로 인수 검토…대규모 배달대행업체 탄생하나
zdnet.co.kr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from zdnet.co.kr Daily Mail and Mail on Sunday newspapers.

South koreaAgencies shinhan bankKorea investmentKorea investment partnersNaver chief technology officerதெற்கு கொரியாகொரியா முதலீடுகொரியா முதலீடு கூட்டாளர்கள்

Mamamoo s agency, Rainbowbridge World, announces plans to go public

Mamamoo s agency, Rainbowbridge World, announces plans to go public
econotimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from econotimes.com Daily Mail and Mail on Sunday newspapers.

South koreaKim jin wooKorean exchangeRainbowbridge worldHybe labelKorea heraldMirae asset securitiesPosco capitalKorea investment partnersKorea economic dailyKim do hoonதெற்கு கொரியாகிம் ஜின் வூகொரியன் பரிமாற்றம்கொரியா ஹெரால்ட்மீரே சொத்து பத்திரங்கள்

SoftBank s Bet On Swiggy Gets CCI Nod As Food Delivery Race Heats Up

SoftBank s Bet On Swiggy Gets CCI Nod As Food Delivery Race Heats Up
inc42.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from inc42.com Daily Mail and Mail on Sunday newspapers.

South koreaMeituan dianpingZomato swiggySoftbank vision fundCompetition commission of indiaNational restaurant association of indiaCompetition commissionVision fundSwiggy genieSpark impactKorea investment partnersBrewing for zomatoNational restaurant associationதெற்கு கொரியாஜோமத்தோ ஸ்விக்கிசாப்ட் பேங்க் பார்வை நிதி

[제약 바이오 이모저모] 신풍제약 피라맥스, 코로나19 임상 2상서 유의성 확보 실패

[제약 바이오 이모저모] 신풍제약 “피라맥스, 코로나19 임상 2상서 유의성 확보 실패” 등록 2021-07-10 오전 11:00:00 수정 2021-07-10 오전 11:00:00 △신풍제약 “피라맥스, 코로나19 임상 2상서 유의성 확보 실패” 신풍제약(019170)은 코로나19 치료제로 개발 중인 ‘피라맥스’의 국내 임상 2상 시험에서 주평가지표의 통계적 유의성을 확보하지 못했다고 5일 밝혔다. 회사는 피라맥스 유효성을 평가하고자 ‘코로나19 바이러스가 음성으로 전환된 환자의 비율’(음전율)을 일차평가변수로 설정했다. 하지만 피라맥스 투여군(52명)과 대조군(58명)에서 음전율에 차이가 없어 일차평가변수 목표치를 달성하지 못했다. 다만 신풍제약은 일부 지표에서 피라맥스가 코로나19 바이러스를 억제하고 중증으로 악화하는 비율을 낮출 가능성을 보였다며 후속 임상을 계속�

United kingdomSaudi arabiaUnited arab emiratesSouth koreaLife sciencesSafety divisionDrug division is medicineJapan clinicalIndonesia clinicalClinical progressDecember japanChinese clinicalCelltrion brazilDrug divisionMiddle eastKorea investment partners